Doxorubicin is an anthracycline antibiotic with antineoplastic activity produced by the bacterium Streptomyces peucetius var. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
Structure of 25316-40-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
1 g | $398 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Title | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|---|
NCT00000626 | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | HIV Infections | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000658 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | Sarcoma, Kaposi | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000689 | Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | Lymphoma, Non-Hodgkin | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000703 | Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members | Lymphoma, Non-Hodgkin | National Institute of Allergy and Infectious Diseases (NIAID) | Completed |
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00892 | N-(Iodoacetamido)-Doxorubicin | 114390-30-6 | |
1547491-85-9 | N-([1,1'-biphenyl]-4-yl)-[1,1':3',1''-terphenyl]-4'-amine | 1547491-85-9 | |
BADC-00042 | Daunorubicin | 20830-81-3 | |
BADC-00039 | Doxorubicin | 23214-92-8 | |
BADC-01122 | Doxorubicin-SMCC | 400647-59-8 | |
BADC-00363 | Aldoxorubicin hydrochloride | 480998-12-7 | |
BADC-01412 | MA-PEG4-VC-PAB-DMAE-Doxorubicin | ||
BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | ||
BADC-01463 | Azide-PEG4-VC-PAB-Doxorubicin | ||
BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.